Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Purpose of fibrate medicine, medicine composition, and purpose of composition

A technology of fibrate and composition, applied in the field of medicine, can solve the problems of many adverse reactions and drug resistance of other inhibitors, and achieve the effect of improving EGFR-TKIs drug resistance

Inactive Publication Date: 2020-10-13
CHINA PHARM UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the secondary mutation of EGFR T790M, the third-generation EGFR-TKIs osimertinib and others have been developed. The therapeutic effect is remarkable and the safety is high. However, the triple mutation of EGFR C797S will still occur during use, leading to drug resistance
In order to solve the problem of drug resistance, EGFR-TKIs combined with other therapeutic measures have been used clinically, but the combination of radiotherapy and chemotherapy and other inhibitors has many adverse reactions. How to find a better combination of drugs is an important direction for future development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purpose of fibrate medicine, medicine composition, and purpose of composition
  • Purpose of fibrate medicine, medicine composition, and purpose of composition
  • Purpose of fibrate medicine, medicine composition, and purpose of composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] 1. The relationship between cholesterol efflux pathway and gefitinib resistance in NSCLC

[0033] 1.1 Experimental materials

[0034] 1.1.1 Experimental cell lines

[0035] Non-small cell lung cancer gefitinib-sensitive PC-9 cell lines; gefitinib-resistant PC-9 / GR, H1650, H1975, A549 cell lines.

[0036] 1.2 Experimental reagents

[0037]Gefitinib, CCK-8 kit, DMEM high glucose medium, fetal bovine serum, penicillin and streptomycin mixture, trypsin, cholesterol assay kit, PPARα antibody, LXRα antibody, ABCA1 antibody, GAPDH antibody.

[0038] 1.3 Experimental method

[0039] 1.3.1 Cell culture

[0040] PC-9, PC-9 / GR, H1650, H1975 and A549 cell lines were cultured in DMEM high-glucose medium containing 10% FBS, 100U / mL penicillin, 100U / mL streptomycin at 37°C in 5% CO 2 in the cell culture incubator.

[0041] 1.3.2 Detection of cell proliferation by CCK-8 method

[0042] When the cell density of PC-9, PC-9 / GR, H1650, H1975 and A549 grows to 90%, after digestion an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a purpose of fibrate medicine, a medicine composition, and a purpose of the composition. The invention discloses the purpose of the fibrate medicine in enhancement of sensitivity of tumor cells or tumor on EGFR-TKIs or reduction of medicine resistance of tumor cells or tumor on EGFR-TKIs. The invention also discloses a synergistic effect of the medicine composition containing the fibrate medicine on treatment of tumor, particularly non-small cell lung cancer.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a use of fibrates, a pharmaceutical composition and the use of the composition. Background technique [0002] Lung cancer is the abbreviation of primary bronchial lung cancer. The global cancer status report shows that lung cancer is the cancer with the highest incidence rate (11.6%) and mortality rate (18.4%) in both sexes. Lung cancer can be divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) according to histopathological features. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers, including adenocarcinoma, squamous cell carcinoma and large cell carcinoma, of which the two subtypes of adenocarcinoma and squamous cell carcinoma are the most common. [0003] At present, the diagnosis and treatment model of lung cancer has shifted from the cellular level to the molecular level-based precision medicine, and molecular targeted therapy dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/216A61K31/192A61K31/5377A61K31/517A61K31/519A61P35/00A61P11/00A61P3/06
CPCA61K31/192A61K31/216A61K31/517A61K31/519A61K31/5377A61K45/00A61P3/06A61P11/00A61P35/00A61K2300/00
Inventor 丁选胜王美飒韩秋爽
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com